# Gyroscope Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gyroscope-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.gyroscopetx.com
- Total disclosed funding: $258M
- Latest round: Series C (Mar 29, 2021)
- Investors on record: 6

## About

Based in London, UK, and founded in 2016, Gyroscope Therapeutics Limited operates as a clinical-stage gene therapy company that develops gene therapies for ocular diseases. The company was founded by Khurem Farooq. In March 2021, Gyroscope Therapeutics Limited raised its latest Series C funding from Forbion. 

Gyroscope Therapeutics Limited is a developer of a gene therapy GT005 a treatment for eye diseases.

Gyroscope Therapeutics Limited plans to use its funding from March 2021 to advance the clinical development of GT005 lead gene therapy. The company also plans to list on the Nasdaq under the symbol VISN.

## Funding rounds

- Series C, Mar 29, 2021, $170M — Sofinnova Investments, T Rowe Price, Forbion, Syncona, Fosun Pharma, Cambridge Innovation Capital
- Series B, Sep 3, 2019, $62M — Syncona, Cambridge Innovation Capital
- Series A, Feb 4, 2019, $19M — Cambridge Innovation Capital
- Seed, May 12, 2016, $7.7M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Seed, Series B, Series C
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A, Series B, Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- Fosun Pharma — Series C